H&Q Life Sciences Investors

abrdn Life Sciences Investors operates as a closed-end fund dedicated to achieving long-term capital appreciation by primarily investing in public equity securities of life sciences companies. The fund’s strategy involves rigorous selection across global public markets, focusing on a diverse range of sub-sectors including biotechnology, pharmaceuticals, and medical devices. This approach enables a broad exposure to the rapidly evolving healthcare innovation landscape.

The fund traces its origins to H&Q Life Sciences Investors, initially launched on May 8, 1992, as an offering from the prominent investment bank Hambrecht & Quist, founded by Bill Hambrecht and George Quist in 1968. Over time, the fund’s management transitioned to Tekla Capital Management. Subsequently, abrdn acquired these healthcare fund management capabilities, integrating the expertise into its broader investment offerings and continuing the fund's mandate.

The fund serves investors seeking managed exposure to the specialized and growth-oriented life sciences industry, offering a vehicle for capital growth within this critical sector. Its overarching vision is to provide consistent long-term appreciation by diligently identifying and investing in promising life sciences entities that are poised to drive future advancements and market development.